Upstream Bio
Waltham · Founded 2021
About Upstream Bio
Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma. They are clinical-stage monoclonal antibodies that inhibit the TSLP receptor, a validated target located upstream of various signaling cascades that influence a range of immune cells that are important in common and unusual illnesses.
Company Facts
- Founded: 2021
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Total funding: $408.0M
- Funding stage: IPO
- Last round: Series B (Jun 2023)
- Ticker: nasdaq:UPB
- Website: https://www.upstreambio.com
- Phone: +1-800-539-0289
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/upstream-bio-51853 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.